


## Triggered Release of a potent LPAAT- $\beta$ inhibitor from inactive prodrugs to kill cancer cells


C. Schuppisser<sup>1</sup>, S. Yasmin<sup>1</sup>, M. Poirier<sup>1</sup>, G. T. Giuffredi<sup>1</sup>, H. Personne<sup>1</sup>, J. L. Reymond<sup>1\*</sup>

<sup>1</sup>University of Bern, Department of Chemistry, Biochemistry and Pharmaceutical Sciences, Freiestrasse 3, 3012 Bern, Switzerland

Lysophosphatidic acid acyltransferase  $\beta$  (LPAAT- $\beta$ ) is an enzyme controlling signaling pathway in mammalian cells and a potential cancer target.[1] In our hands however, the enzyme appeared to be similarly expressed in several cancer and non-cancer cells, and the nanomolar LPAAT- $\beta$  inhibitors CT32228 and aminotriazine (**1**) appeared to be equally cytotoxic to both cell types.[2] Herein we report our investigation of a prodrug strategy to target **1** to cancer cells. By a structure-activity relationship study, we identified two potential vectors for connecting **1** to a cleavable linker. We then elaborated substituent and linker chemistry and obtained a redox-triggered release of active analogs of **1** from peptide-conjugated prodrugs.



CT32228



LPAAT- $\beta$  inhibitor (**1**)  
IC<sub>50</sub> = 51 nM

[1] Michael Coon, Alexey Ball, Jeannine Pound, Sophe Ap, David Hollenback, Thayer White, John Tulinsky, Lynn Bonham, Deborah K. Morrison, Robert Finney, Jack W. Singer, *Mol. Cancer Ther.*, **2003**, 2, 1067-1078.

[2] Marion Poirier, Mahendra Awale, Matthias A. Roelli, Guy T. Giuffredi, Lars Ruddigkeit, Lasse Evensen, Amandine Stooss, Serafina Calarco, James B. Lorens, Roch-Philippe Charles, Jean-Louis Reymond, *ChemMedChem*, **2019**, 14, 224-236.